Cancers, Vol. 11, Pages 1808: hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status

Cancers, Vol. 11, Pages 1808: hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status Cancers doi: 10.3390/cancers11111808 Authors: Jerome Raffenne Remy Nicolle Francesco Puleo Delphine Le Corre Camille Boyez Raphael Marechal Jean François Emile Peter Demetter Armelle Bardier Pierre Laurent-Puig Louis de Mestier Valerie Paradis Anne Couvelard Jean Luc VanLathem John R. MacKey Jean-Baptiste Bachet Magali Svrcek Jerome Cros Gemcitabine is still one of the standard chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC). Gemcitabine uptake into tumor cells is mainly through the human equilibrative nucleoside transport 1 (hENT1). It was therefore proposed as a potential predictive biomarker of gemcitabine efficacy but reports are conflicting, with an important heterogeneity in methods to assess hENT1 expression. A multicenter cohort of 471 patients with a resected PDAC was used to assess simultaneously the predictive value of the 2 best described hENT1 antibodies (10D7G2 and SP120). Three additional antibodies and the predictive value of hENT1 mRNA were also tested on 251 and 302 patients, respectively. hENT1 expression was assessed in 54 patients with matched primary tumors and metastases samples. The 10D7G2 clone was the only hENT1 antibody whose high expression was associated with a prolonged progression free survival and overall survival in patients who received adjuvant gemc...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research